Arbutus Biopharma Corporation ABUS Business Segments — Restructuring costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's business segments — restructuring costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's business segments — restructuring costs?
- Arbutus Biopharma Corporation (ABUS) reported business segments — restructuring costs of $0 in Q1 2026.
- How has Arbutus Biopharma Corporation's business segments — restructuring costs changed year-over-year?
- Arbutus Biopharma Corporation's business segments — restructuring costs decreased by 100.0% year-over-year, from $12.37M to $0.
- What does business segments — restructuring costs mean?
- These are non-recurring expenses related to organizational changes, such as workforce reductions, facility consolidations, or strategic pivots. High levels of these costs indicate significant operational transformation or efforts to improve long-term cost structures.